Nanomedicine opportunities for cardiovascular disease with perfluorocarbon nanoparticles.
Nanomedicine promises to enhance the ability of clinicians to address some of the serious challenges responsible for cardiovascular mortality, morbidity and numerous societal consequences. Targeted imaging and therapy applications with perfluorocarbon nanoparticles are relevant to a broad spectrum of cardiovascular diseases, ranging from asymptomatic atherosclerotic disease to acute myocardial infarction or stroke. As illustrated in this article, perfluorocarbon nanoparticles offer new tools to recognize and characterize pathology, to identify and segment high-risk patients and to treat chronic and acute disease.
Lanza
Gregory M
GM
Division of Cardiology, Washington University Medical School, Cortex Building, St Louis, MO 63108, USA. greg@cvu.wustl.edu
Winter
Patrick M
PM
Caruthers
Shelton D
SD
Hughes
Michael S
MS
Cyrus
Tillmann
T
Marsh
Jon N
JN
Neubauer
Anne M
AM
Partlow
Kathy C
KC
Wickline
Samuel A
SA
D000818:Animals; D004337:Drug Carriers / Q000737:chemistry; D016503:Drug Delivery Systems / Q000379:methods; D005466:Fluorocarbons / Q000737:chemistry*; D006801:Humans; D050997:Nanomedicine / Q000379:methods*; D053758:Nanoparticles / Q000737:chemistry*; D036103:Nanotechnology / Q000379:methods; D004364:Pharmaceutical Preparations / Q000008:administration & dosage / Q000737:chemistry
D004337:Drug Carriers; D005466:Fluorocarbons; D004364:Pharmaceutical Preparations